Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 12/20 | 0.47 |
| ▸ | TNIK | Q9UKE5 | 3/20 | 0.46 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26175354 | 0.93 | MAP3K11 (0.52) | ALKTNIKMAP3K11 | |
| SCHEMBL26175355 | 0.92 | KIT (0.53) | ALKTNIKMAP3K11KIT | |
| SCHEMBL26175265 | 0.89 | CAMKK2 (0.52) | TNIK | |
| SCHEMBL26174754 | 0.87 | TNIK (0.42) | TNIKMAP3K11KIT | |
| SCHEMBL26176246 | 0.86 | HAT1 (0.39) | — | |
| SCHEMBL30398339 | 0.86 | HAT1 (0.39) | — | |
| SCHEMBL30399298 | 0.86 | NEK1 (0.48) | TNIKMAP3K11KIT | |
| SCHEMBL30400480 | 0.86 | KIT (0.47) | TNIKMAP3K11KIT | |
| SCHEMBL26175305 | 0.86 | KIT (0.47) | TNIKMAP3K11KIT | |
| SCHEMBL26175469 | 0.86 | NEK1 (0.48) | TNIKMAP3K11KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4415817-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AS DYRK1A INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | claimed |
| WO-2023064349-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AS DYRK1A INHIBITORS | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | claimed |
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | ALK 2142/4885TNIK 500/4885MAP3K11 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.